Physician profile
Patrick D Whipple
NPI 1457513350
$2,027.07
in general payments reported to CMS, 2019-2025
25 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $314 · 2021: $423 · 2022: $224 · 2023: $315 · 2024: $286 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $395.41 | 2019-2024 | Vraylar |
| Lilly USA, LLC | $279.55 | 2019-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $215.99 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals Lp | $191.05 | 2020-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $116.64 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $100.10 | 2019-2021 | |
| Genentech USA, INC. | $98.86 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.87 | 2023-2024 | |
| Corcept Therapeutics | $84.67 | 2025 | Korlym |
| Pfizer INC. | $73.33 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $56.95 | 2020-2022 | |
| Welch Allyn | $52.60 | 2021 | |
| Inari Medical, INC. | $50.58 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.25 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.74 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $19.37 | 2021 | |
| Solventum Corporation | $18.34 | 2025 | Prevena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.80 | 2024 | Caplyta |
| Amgen INC. | $17.27 | 2025 | Otezla, Repatha |
| Currax Pharmaceuticals LLC | $15.90 | 2025 | Onzetra Xsail, Contrave |
| Medtronic, INC. | $15.22 | 2025 | Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $15.07 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.81 | 2019 | |
| Melinta Therapeutics, LLC | $12.73 | 2019 | |
| Glaxosmithkline, LLC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Whipple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.